Access Accelerated (AA) is a biopharmaceutical industry led collaboration that seeks to reduce barriers to prevention, treatment and care for NCDs in lower- and middle-income countries through health systems strengthening and alignment with Universal Health Coverage (UHC) objectives. AA recognizes that only by putting the needs of people living with NCDs first and acting in collaboration with governments, civil society, multilaterals, NGOs and others can the global community make measurable and sustainable progress against NCDs in developing countries.
Together, AA and IFPMA recognize an urgent need to better understand and take steps to address challenges to strengthening health systems for NCDs, particularly highlighting context specific needs and the perspectives of people living with NCDs in line with nationally identified priorities. However, a coordinated response – amongst and within sectors – is the only way to respond effectively and sustainably to the systemic challenges to NCD prevention, treatment and care. No single stakeholder can address NCDs alone and the biopharmaceutical industry seeks to be a meaningful and solutions-oriented partner to develop sustainable, appropriate and affordable solutions at global and local levels in the context of UHC. Now is the time for coordinated and collective action in the fight against NCDs to improve the lives of people.